Select Publications
Journal articles
2000, 'Functional characterization of the NCC27 nuclear protein in stable transfected CHO-K1 cells', Federation of American Societies for Experimantal Biology Journal, 14, pp. 1171 - 1178
,2000, 'Hyperkalaemia and acidosis modify HERG channel biophysical properties and antagonise inhibition by sotalol', Heart, Lung and Circulation, 9, pp. A131 - A131, http://dx.doi.org/10.1046/j.1443-9506.2000.07650.x
,2000, 'Inhibiton of HERG potassium channels by the antimalarial agent halofantrine', British Journal of Pharmacology, 130, pp. 1967 - 1975
,2000, 'N-3 polyunsaturated fatty acids and cardiac mortality', Australian and New Zealand Journal of Medicine, pp. 246 - 251
,2000, 'Potent blockade by quinidine of the Kv4.3 current: Significance with regard to treatment of the brugada syndrome', Heart, Lung and Circulation, 9, pp. A92 - A92, http://dx.doi.org/10.1046/j.1443-9506.2000.06115.x
,2000, 'The antipsychotic agents thioridazine, chlorpromazine and clozapine block the human-ether-a-go-go-related gene (HERG) potassium channel: Cellular mechanism for proarrhythmia', Heart, Lung and Circulation, 9, pp. A109 - A109, http://dx.doi.org/10.1046/j.1443-9506.2000.06796.x
,1999, 'Blockade by N-3 polyunsaturated fatty acid of the Kv4.3 current stably expressed in Chinese Hamster ovary cells', British Journal of Pharmacology, 127, pp. 941 - 948
,1999, 'Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate.', British Journal of Pharmacology, 127, pp. 243 - 251
,1999, 'Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states', British Journal of Pharmacology, 128, pp. 444 - 450
,1998, 'International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina', Circulation, 97, pp. 2386 - 2395, http://dx.doi.org/10.1161/01.CIR.97.24.2386
,1998, 'Alternative hypothesis for efficacy of macrolides in acute coronary syndromes', Lancet, 351, pp. 1858 - 1859, http://dx.doi.org/10.1016/S0140-6736(05)78804-8
,1998, 'Comparative study of the effects of erythromycin and roxithromycin on action potential duration and potassium currents in canine Purkinje fibers and rabbit myocardium', Journal of Cardiovascular Pharmacology and Therapeutics, 3, pp. 29 - 36, http://dx.doi.org/10.1177/107424849800300104
,1998, 'Therapeutic drug monitoring: Antiarrhythmic drugs', British Journal of Clinical Pharmacology, 46, pp. 307 - 319, http://dx.doi.org/10.1046/j.1365-2125.1998.t01-1-00768.x
,1998, 'The death of a normal healthy volunteer in a human research project: implications for Australian clinical research', Medical Journal of Australia, 168, pp. 449 - 451, http://dx.doi.org/10.5694/j.1326-5377.1998.tb139026.x
,1998, 'Therapeutic Drug monitoring of antiarrhythmic drugs', British Journal of Clinical Pharmacology, pp. 307 - 319
,1997, 'Chapter 26 Antiarrhythmic drugs', Principles of Medical Biology, 8, pp. 519 - 527, http://dx.doi.org/10.1016/S1569-2582(97)80051-7
,1997, 'Safety of chloramphenicol eyedrops', Australian and New Zealand Journal of Ophthalmology, 25, pp. 3
,1997, 'Modulation of the electrophysiologic actions of E-4031 and dofetilide by hyperkalemia and acidosis in rabbit ventricular myocytes', Journal Cardiovascular Pharmacology and Therapentics, 2, pp. 205 - 212
,1997, 'Molecular cloning and expression of a chloride ion channel of cell nuclei.', The Journal of Biological Chemistry, pp. 12575 - 12582
,1997, 'The novel class 111antiarrhythymic agent MS-551 blocks the inward rectifier with greater potency than sotalol or E-4031: possible relevance to reverse use-dependence', Journal Cardiovascular Pharmacology and Therapentics, 2, pp. 39 - 46
,1997, 'The place of amiodarone: an overview of the four recent large amidarone trials', Australian and New Zealand Journal of Medicine, pp. 582 - 590
,1996, 'Effect of the class III antiarrhythmic agent E-4031 on the ATP-sensitive potassium channel in rabbit ventricular myocytes', Pharmacology and Toxicology, 78, pp. 89 - 93, http://dx.doi.org/10.1111/j.1600-0773.1996.tb00186.x
,1996, 'Proarrhythmic complications of sotalol', Australian and New Zealand Journal of Medicine, 26, pp. 147 - 149, http://dx.doi.org/10.1111/j.1445-5994.1996.tb00875.x
,1996, 'Beta-blockers for ventricular arrhythmia:have we underestimated their value?', Australian and New Zealand Journal of Medicine, pp. 689 - 696
,1996, 'Blockade of the ATP-sensitive potassium channel in rabbit ventricular myocytes by the class III anti-arrhythmic agent E-4031', Pharmacology and Toxicology, pp. 89 - 93
,1996, 'Chloride ion channels are associated with adherence of lympahatic endothelial cells', Microvascular Research, pp. 200 - 209
,1996, 'Class III antiarrhythmic effects of dofetilide in rabbit atrial myocardium', Journal Cardiovascular Pharmacology and Therapentics, 1, pp. 229 - 234
,1996, 'Class III antiarrhythmic effects of dofetilide in rabbit atrial myocardium', Journal Cardiovascular Pharmacology and Therapentics, 1, pp. 229 - 234
,1996, 'Differential effects of antiarrhythmic agents on post pause repolarisation in cardiac Purkinje fibres', Clinical and Experimental Pharmacology and Physiology, pp. 825 - 829
,1996, 'Effect of Dofetilide and d-Sotalol on the ATP-sensitive potassium channel of rabbit ventricular Myocytes', Journal Cardiovascular Pharmacology and Therapentics, pp. 307 - 312
,1996, 'Effect of E-4031, sotalol and MS-551 on single inward-rectifier potassium channels in rabbit heart cells', Japanese Heart Journal, pp. 275 - 276
,1996, 'Is this Arrhythmia significant?', Australian Family Physician, pp. 1045 - 1050
,1995, 'Inhibition of ATP‐Sensitive Potassium Channels in Cardiac Myocytes by the Novel Class III Antiarrhythmic Agent MS‐551', Pharmacology & Toxicology, 77, pp. 65 - 70, http://dx.doi.org/10.1111/j.1600-0773.1995.tb01915.x
,1995, 'Human macrophages contain a stretch-sensitive potassium channel that is activated by adherence and cytokines', Journal of Membrane Biology, 147, pp. 305 - 315
,1995, 'Inhibition of ATP-sensitive potassium channels in cardiac mycytes by a novel antiarrhymthmic agent, MS-551', Pharmacology and Toxicology, 160, pp. 202 - 205
,1994, 'Treatment of atrial fibrillation.', Australian family physician, 23, pp. 924 - 931
,1994, 'Antiarrhythmic drugs', Medical Journal of Australia, 160, pp. 202 - 205, http://dx.doi.org/10.5694/j.1326-5377.1994.tb126603.x
,1994, 'Effects of disopyramide and flecainide on the kinetics of inward rectifier potassium channels in rabbit heart muscle', British Journal of Pharmacology, 111, pp. 873 - 879, http://dx.doi.org/10.1111/j.1476-5381.1994.tb14819.x
,1994, 'Quinidine but not disopyramide prolongs cardiac purkinje fiber action potentials after a pause', Journal of Cardiovascular Pharmacology, 23, pp. 833 - 837, http://dx.doi.org/10.1097/00005344-199405000-00021
,1993, 'Action potential prolongation exhibits simple dose-dependence for sotalol, but reverse dose-dependence for quinidine and disopyramide: Implications for proarrhythmia due to triggered activity', Journal of Cardiovascular Pharmacology, 21, pp. 316 - 322, http://dx.doi.org/10.1097/00005344-199302000-00019
,1993, 'Atrial fibrillation [7]', Medical Journal of Australia, 158, pp. 138, http://dx.doi.org/10.5694/j.1326-5377.1993.tb137555.x
,1993, 'Class III antiarrhythmic action: The way forward?', Medical Journal of Australia, 158, pp. 732 - 733, http://dx.doi.org/10.5694/j.1326-5377.1993.tb121952.x
,1993, 'Digitalis for patients with heart failure in sinus rhythm', Medical Journal of Australia, 159, pp. 647 - 649, http://dx.doi.org/10.5694/j.1326-5377.1993.tb138076.x
,1993, 'Effects of hyperkalaemia on the depression of maximum rate of depolarization by class I antiarrhythmic agents in guinea‐pig myocardium', British Journal of Pharmacology, 108, pp. 255 - 261, http://dx.doi.org/10.1111/j.1476-5381.1993.tb13471.x
,1993, 'Lidocaine shows greater selective depression of depolarized and acidotic myocardium than propafenone: Possible implications for proarrhythmia', Journal of Cardiovascular Pharmacology, 21, pp. 47 - 55, http://dx.doi.org/10.1097/00005344-199301000-00008
,1992, 'Subclassification of Class I antiarrhythmic drugs: Enhanced relevance after CAST', Cardiovascular Drugs and Therapy, 6, pp. 519 - 528, http://dx.doi.org/10.1007/BF00055611
,1992, 'Recent developments in the pharmacotherapy of cardiac failure', Medical Journal of Australia, 157, pp. 292 - 294, http://dx.doi.org/10.5694/j.1326-5377.1992.tb137175.x
,1992, 'Treatment of atrial fibrillation: time for change?', Medical Journal of Australia, 157, pp. 78 - 80, http://dx.doi.org/10.5694/j.1326-5377.1992.tb137029.x
,1991, 'DIFFERENTIAL EFFECTS ON ACTION POTENTIAL DURATION OF CLASS IA, B AND C ANTIARRHYTHMIC DRUGS: MODULATION BY STIMULATION RATE AND EXTRACELLULAR K+ CONCENTRATION', Clinical and Experimental Pharmacology and Physiology, 18, pp. 533 - 541, http://dx.doi.org/10.1111/j.1440-1681.1991.tb01488.x
,1991, 'Effects of hyperkalemia, acidosis, and hypoxia on the depression of maximum rate of depolarization by class I antiarrhythmic drugs in guinea pig myocardium: Differential actions of class Ib and Ic agents', Journal of Cardiovascular Pharmacology, 18, pp. 51 - 60, http://dx.doi.org/10.1097/00005344-199107000-00008
,